Barry Callebaut has halted manufacturing operations at its Weize chocolate plant in Belgium as a precautionary measure while conducting its root cause analysis and risk assessment after detecting salmonella in a production lot.
The company identified lecithin as the source of the contamination.
All chocolate products manufactured at the facility since June 25 have been placed on hold.
After the analysis, the lines will be cleaned and sanitized before production can resume.
Barry Callebaut, which informed the Belgian food authorities (FAVV) about the incident, said that their robust food safety programs allowed them to identify lecithin as the source of the contamination quickly.
The company added that they are reaching out to all customers who may have received impacted products.
The news comes after Ferrero temporarily suspended production at its Arlon facility in Belgium after the site was linked to a salmonella outbreak.


Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Australia’s Labour Market Weakens as November Employment Drops Sharply
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation
Fed’s Dovish Tone Sends Dollar Lower as Markets Price In More Rate Cuts
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform
Gold Prices Dip as Markets Absorb Dovish Fed Outlook; Silver Eases After Record High
Gold Prices Hold Firm as Markets Await Fed Rate Cut; Silver Surges to Record High
Asian Stocks Slip Ahead of Fed Decision as China Deflation Concerns Deepen
BOJ Expected to Deliver December Rate Hike as Economists See Borrowing Costs Rising Through 2025
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 



